Meeting
2020 Genitourinary Cancers Symposium
Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.
Authors
Jones Nauseef
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
Jones Nauseef , Panagiotis J. Vlachostergios , Ana M. Molina , David M. Nanus , Cora N. Sternberg , Timothy D McClure , Douglas Scherr , M. Laura Martin , Giorgio Inghirami , Olivier Elemento , Scott T. Tagawa , Bishoy Morris Faltas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT03837821
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS606)
Abstract #
TPS606
Poster Bd #
P2
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.
First Author: Jones Nauseef
Poster
2023 ASCO Annual Meeting
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
First Author: Jerome Fayette
Poster
2023 ASCO Annual Meeting
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
First Author: Gertjan VAN HAL
Poster
2023 ASCO Annual Meeting
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
First Author: Thomas W. Flaig